랜턴 파마LTRN 주가

[D] D

Lantern Pharma Receives Successful Response To Its Recent FDA Type C Meeting Request Focused On The Ongoing Phase 2 HARMONIC Trial Of LP-300 In Never-Smokers With Advanced Non-Small Cell Lung Cancer Adenocarcinoma

In its written responses to Lantern's Type C meeting request, the FDA raised no objections to key proposed protocol amendments, providing a more focused, clearer regulatory path forward for the HARMONIC™ trial and

♻️ 재탕12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with...

Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 28.57 percent increase over losses of $(0.42) per share from

Earnings Scheduled For May 15, 2026

[10-Q] 분기 실적 — 10-Q

[SCHEDULE 13D/A] SCHEDULE 13D/A

♻️ 재탕[8-K] 중대 사건 — 8-K